Business
New £4.3m Challenge Study Contract Win
New £4.3m Challenge Study Contract Win.
About this update from Hvivo Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 2187A\n Open Orphan PLC\n 28 September 2020\n \n \n \n \n 28 September 2020\n \n \n Open Orphan plc\n \n \n (\"Open Orphan\" or the \"Company\")\n \n \n New £4.3m Challenge Study Contract Win with Global Top 10 Vaccine Company\n \n \n \n \n \n Interim Results to be published Wednesday 30th September 2020\n \n \n \n \n \n Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new £4.3 million contract to conduct a human viral challenge study utilising one of our 8 traditional challenge study models for another of the global top 10 vaccine companies. \n \n \n \n \n \n This trial will be conducted in the Company's dedicated human viral challenge quarantine unit in London with all volunteers recruited through hVIVO's volunteer recruitment website, \n www.flucamp.com\n . The hVIVO unit is Europe's only commercial 24-bedroom quarantine clinic with on-site virology laboratory. \n \n \n \n \n \n Work on this major new contract has started already and the contract is expected to be delivered in Q1 2021 with the majority of revenues being generated in H1 2021. It is a further example of Open Orphan delivering on its pipeline and stated strategy of winning sizeable contracts. \n \n \n \n \n \n The Company's Interim Results will be published on the morning of Wednesday the 30th of September 2020, analyst conference call scheduled for 10.30am on the 30th of September.\n \n \n \n \n \n Cathal Friel, Executive Chairman, Open Orphan, said:\n \n \n \n \n \n \"Open Orphan continues to execute on its substantial pipeline that has been built up by the expertise and experience of our professional and hardworking teams in \n hVIVO\n and \n Venn Life Sciences\n . We are focused on continuing to deliver large and profitable contracts which demonstrate hVIVO's position as the world leader in the testing of vaccines and antivirals using human challenge clinical trials. \n \n \n \n \n \n \n Our stated objectives when we acquired hVIVO in January of this year was to increase its 24-bedroom quarantine clinic annual utilisation from its traditional 20-25% utilisation up to maximum capacity and to build out a...